Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant

Fig. 5

In vivo drug response to BYL719 or fulvestrant alone and combined in the HBCx-91 PDX model. a Effect of the different treatments on HBCx-91 tumor growth. Each treatment included 10 mice; the y-axis indicates the mean of RTV + SD. b PLA was performed and analyzed as in Fig. 2. c RT-QPCR was performed from frozen tumor for ERG expression. d IHC staining was performed on formalin-fixed paraffin-embedded PDX tumors using anti-ERα, anti-P-AKT (S473), and anti-P-S6 riboprotein (S235/6) antibodies. Quantification of highly, medium, and negative cells was performed as described in the “Materials and methods” section. Significance (P value) between treatments and controls were performed using the t test. ns: not significant

Back to article page